Form 4: Provectus Biopharmaceuticals CEO Edward Pershing Reports Conversion of Convertible Note into Preferred Stock

CEO Edward Pershing reports the conversion of an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock.

Summary

• On July 20, 2024, Edward Pershing, CEO of Provectus Biopharmaceuticals, reported a transaction involving the conversion of an 8% unsecured convertible promissory note into 47,199 shares of Series D-1 Convertible Preferred Stock.
• The conversion occurred automatically twelve months after the issue date of the note, at a price of $2.862 per share.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock.
• Pershing directly owns 1,414,652 shares of common stock following the reported transactions.
• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing a routine conversion of a convertible note. It doesn't inherently convey positive or negative sentiment.

Future Outlook

The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

Industry Context

This filing is a routine disclosure related to executive compensation and equity ownership, common in the biopharmaceutical industry.

Stakeholder Impact

• The conversion of preferred stock to common stock could potentially dilute existing shareholders' equity.

Key Dates